Innovative Healthcare Institute highlighted key session updates on LinkedIn for the upcoming Best of Lung Cancer Conference, an educational event focused on the latest advances and practice-changing data in lung cancer care, including emerging therapies, diagnostics, and personalized treatment approaches:
“1.The perioperative treatment landscape for early-stage NSCLC continues to evolve.
Join Alex Adjei of Cleveland Clinic Cancer Center at the Best of Lung Cancer Conference for a focused review of neoadjuvant and adjuvant systemic treatment strategies.
Dr. Adjei will also lead a case-based discussion examining how emerging evidence can inform clinical decisions across the perioperative treatment journey.
2.How can comprehensive molecular profiling help clinicians make more informed decisions throughout the NSCLC disease trajectory?
At the Best of Lung Cancer Conference, Christian Rolfo of The Ohio State University will discuss current and emerging approaches to molecular testing and monitoring, including:
- IHC, NGS, and panomics
- Tissue versus liquid biopsy
- Repeat testing strategies
- Molecular residual disease utilization
Join oncology experts from across the region for a practical, evidence-focused day of education, clinical discussion, and professional connection.
3.Antibody-drug conjugates are expanding the therapeutic conversation in thoracic oncology.
At the Best of Lung Cancer Conference, Alejandro Calvo of Kettering Health will review the evolving role of ADCs in both SCLC and NSCLC. A companion case presentation will help translate the scientific and clinical discussion into practical decision-making.
Join us for an educational program developed for oncology physicians, advanced practice providers, pharmacists, nurses, researchers, and other healthcare professionals.
October 3, 2026, Cincinnati, Ohio
Register today.
Hosted by Innovative Healthcare Institute, Abdul Rahman Jazieh with support from OncoDaily, American Lung Association, Community Oncology Alliance (COA), and International Oncology Network Solutions (ION).”
HER2 Mutations in NSCLC: Critical Risks of Outdated Terms
